Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory Klein

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
JAMA Neurology|May 8, 2023
Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer DiseaseAntoine Leuzy, Alexa Pichet Binette, Jacob W Vogel, et al.
Journal of Alzheimer'S Disease : JAD|August 23, 2024
Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD)Anuja Neve, Bibha Das, Jakub Wojtowicz, et al.
Annals of Neurology|January 20, 2026
Toward Harmonizing Quantification of Dopamine Neuron Imaging Biomarkers in Parkinson's Disease: The Centamine ScaleZhen Fan, Graham Searle, Gaia Rizzo, et al.
Alzheimer'S Research & Therapy|December 10, 2017
A phase III randomized trial of gantenerumab in prodromal Alzheimer's diseaseSusanne Ostrowitzki, Robert A Lasser, Ernest Dorflinger, et al.
JAMA Neurology|November 18, 2024
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer DiseaseStephen Salloway, Jakub Wojtowicz, Nicola Voyle, et al.
Alzheimer'S Research & Therapy|September 29, 2018
Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's diseaseSusanne Ostrowitzki, Robert A Lasser, Ernest Dorflinger, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentLuka Kulic, Fabien Alcaraz, Gregory Klein, et al.
JAMA Neurology|December 20, 2021
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer DiseaseAntoine Leuzy, Ruben Smith, Nicholas C Cullen, et al.
Journal of Alzheimer'S Disease : JAD|December 17, 2024
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD)Mercè Boada, Anuja Neve, Bibha Das, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentJanice Smith, Catherine J Mummery, Jeffrey L Cummings, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
JAMA Neurology|May 8, 2023
Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer DiseaseAntoine Leuzy, Alexa Pichet Binette, Jacob W Vogel, et al.
Journal of Alzheimer'S Disease : JAD|August 23, 2024
Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD)Anuja Neve, Bibha Das, Jakub Wojtowicz, et al.
Annals of Neurology|January 20, 2026
Toward Harmonizing Quantification of Dopamine Neuron Imaging Biomarkers in Parkinson's Disease: The Centamine ScaleZhen Fan, Graham Searle, Gaia Rizzo, et al.
Alzheimer'S Research & Therapy|December 10, 2017
A phase III randomized trial of gantenerumab in prodromal Alzheimer's diseaseSusanne Ostrowitzki, Robert A Lasser, Ernest Dorflinger, et al.
JAMA Neurology|November 18, 2024
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer DiseaseStephen Salloway, Jakub Wojtowicz, Nicola Voyle, et al.
Alzheimer'S Research & Therapy|September 29, 2018
Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's diseaseSusanne Ostrowitzki, Robert A Lasser, Ernest Dorflinger, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentLuka Kulic, Fabien Alcaraz, Gregory Klein, et al.
JAMA Neurology|December 20, 2021
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer DiseaseAntoine Leuzy, Ruben Smith, Nicholas C Cullen, et al.
Journal of Alzheimer'S Disease : JAD|December 17, 2024
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD)Mercè Boada, Anuja Neve, Bibha Das, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentJanice Smith, Catherine J Mummery, Jeffrey L Cummings, et al.
Pageof 7